Zai Lab's Schizophrenia Drug Application Accepted by Chinese Regulator; Shares Rise

Trading View
2025.01.17 15:20
portai
I'm PortAI, I can summarize articles.

Zai Lab's new drug application for KarXT, aimed at treating schizophrenia in adults, has been accepted by China's National Medical Products Administration. The application is supported by results from various studies, including a phase 1 pharmacokinetics study and a phase 3 study in China. Following the announcement, Zai Lab's shares rose by 2.1%.

Zai Lab said Friday that its new drug application for KarXT to treat adult patients with schizophrenia was accepted by China's National Medical Products Administration.

The application is backed by results from a phase 1 China pharmacokinetics study, the phase 3 China study and data from global Emergent clinical programs, according to the company.

KarXT, or xanomeline and trospium chloride, showed a reduction in positive and negative syndrome scale total score from baseline in the China phase 3 study, Zai Lab added.

Shares of Zai Lab were up 2.1% in recent trading.

Source: Trading View The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.